These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7407335)

  • 41. Disposition of the angiotensin II receptor antagonist L-158,809 in rats and rhesus monkeys.
    Colletti AE; Krieter PA
    Drug Metab Dispos; 1994; 22(2):183-8. PubMed ID: 8013272
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics.
    Elliott HL; Thomson AH; Bryson SM
    Eur J Clin Pharmacol; 1986; 30(3):345-7. PubMed ID: 3732373
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of disopyramide in patients with chronic renal failure.
    Francois B; Mallein R; Rondelet J; Lussignol M
    Eur J Drug Metab Pharmacokinet; 1983; 8(1):85-92. PubMed ID: 6861798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.
    Ward JW; Kinghorn GR
    J Int Med Res; 1976; 4(1 Suppl):49-53. PubMed ID: 1026529
    [No Abstract]   [Full Text] [Related]  

  • 45. Disopyramide concentrations in saliva.
    Aitio ML; Virtanen R; Lammintausta R
    Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):68-72. PubMed ID: 7061181
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.
    Deano DA; Wu D; Mautner RK; Sherman RH; Ehsani AI; Rosen KM
    Chest; 1977 May; 71(5):597-606. PubMed ID: 856558
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disopyramide hemodialysis and kinetics in patients requiring long-term hemodialysis.
    Sevka MJ; Matthews SJ; Nightingale CH; Izard MW; Fieldman A; Chow MS
    Clin Pharmacol Ther; 1981 Mar; 29(3):322-6. PubMed ID: 7471602
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The influence of protein binding on disopyramide clearance.
    Bryson SM; Lawrence JR; Steele WH; Campbell BC; Elliott HL; Sumner DJ
    Eur J Clin Pharmacol; 1982; 23(5):453-6. PubMed ID: 7151851
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pharmacokinetics and protein binding of disopyramide in pigs.
    Pedersen LE; Hermansen K; Olesen HP; Rasmussen SN
    Acta Pharmacol Toxicol (Copenh); 1986 Apr; 58(4):282-8. PubMed ID: 3716823
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration.
    Mikus G; Fischer C; Heuer B; Langen C; Eichelbaum M
    Br J Clin Pharmacol; 1987 Nov; 24(5):561-9. PubMed ID: 3435690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of enzyme induction on the metabolism of disopyramide in man.
    Aitio ML; Mansury L; Tala E; Haataja M; Aitio A
    Br J Clin Pharmacol; 1981 Mar; 11(3):279-85. PubMed ID: 7213529
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gastrointestinal dialysis of disopyramide in healthy subjects.
    Arimori K; Kawano H; Nakano M
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):280-4. PubMed ID: 2737797
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The renal clearance of disopyramide after bolus intravenous injection.
    Lawrence JR; Bryson SM; Sumner DJ; Campbell BC; Whiting B
    Biopharm Drug Dispos; 1979; 1(2):51-7. PubMed ID: 552861
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiarrhythmic and electrocardiographic effects of single oral doses of disopyramide.
    Hulting J; Jansson B
    Eur J Clin Pharmacol; 1977 Jan; 11(2):91-9. PubMed ID: 320015
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lack of dose dependent kinetics of methyl salicylate-2-O-β-D-lactoside in rhesus monkeys after oral administration.
    He Y; Yan Y; Zhang T; Ma Y; Zhang W; Wu P; Song J; Wang S; Du G
    J Ethnopharmacol; 2015 Apr; 164():293-300. PubMed ID: 25571846
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disopyramide kinetics in renal impairment: determinants of interindividual variability.
    Burk M; Peters U
    Clin Pharmacol Ther; 1983 Sep; 34(3):331-40. PubMed ID: 6883909
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A dual-label stable-isotopic protocol is suitable for determination of folate bioavailability in humans: evaluation of urinary excretion and plasma folate kinetics of intravenous and oral doses of [13C5] and [2H2]folic acid.
    Rogers LM; Pfeiffer CM; Bailey LB; Gregory JF
    J Nutr; 1997 Dec; 127(12):2321-7. PubMed ID: 9405581
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous and oral disopyramide after myocardial infarction.
    Nicholls DP; Haybyrne T; Barnes PC
    Lancet; 1980 Nov; 2(8201):936-8. PubMed ID: 6107587
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia.
    Vismara LA; Vera Z; Miller RR; Mason DT
    Am J Cardiol; 1977 Jun; 39(7):1027-34. PubMed ID: 326016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.